PMID

Data

Article Title

Organization

Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.

Dainippon Sumitomo Pharma

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.

Merck Research Laboratories

A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning.

University of Arizona

Design and synthesis of conformationally constrained glucagon analogues.

University of Arizona

The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.

University of Arizona

Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.

University of Arizona

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

Merck Research Laboratories

 

[des His¹, des Phe⁶, Glu⁹]glucagon amide: A newly designed “pure” glucagon antagonist

TBA

 

CP-99,711: a non-peptide glucagon receptor antagonist

TBA

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

Novo Nordisk

New beta-alanine derivatives are orally available glucagon receptor antagonists.

Novo Nordisk

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

Novo Nordisk

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.

Syracuse University

Human glucagon receptor antagonists based on alkylidene hydrazides.

Pfizer

Identification of alkylidene hydrazides as glucagon receptor antagonists.

Pfizer

Development of potent truncated glucagon antagonists.

University of Arizona